Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Skin Problems Due to Treatment with Technology Are Associated with Increased Disease Burden Among Adults with Type 1 Diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Comparison of Continuous Glucose Monitoring Accuracy Between Abdominal and Upper Arm Insertion Sites

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. DIWHY – Motivations, barriers and retention factors of DIY artificial pancreas users in real world use

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Long acting insulin dose response modelling in type 2 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  1. Low carbohydrate diet elevates blood sphingomyelin in people with type 1 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice

    Research output: Contribution to journalReviewResearchpeer-review

  3. Perinatal Whole Blood Zinc Status and Cytokines, Adipokines, and Other Immune Response Proteins

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: In a 4-month follow-up survey, we examined whether treatment with continuous subcutaneous insulin infusion (CSII) and/or continuous glucose monitoring (CGM) in adults with type 1 diabetes was associated with sustained skin problems and whether skin problems were associated with diabetes-related emotional distress.

RESEARCH DESIGN AND METHODS: A total of 111 adult patients completed a follow-up questionnaire concerning skin problems as a result of CSII and/or CGM use. The questionnaire included a patient-reported outcome measure, the Problem Areas in Diabetes (PAID) scale.

RESULTS: Current visible skin problems caused by CSII or CGM use were reported by 51 (46.0%) participants, in 34 (66.7%) of whom skin problems had been reported more than 4 months earlier. Seventy-two (64.9%) participants reported skin problems as a result of CSII use, whereas 38 (74.5%) reported skin problems owing to CGM use at some time. Itching was the most prevalent complaint. CSII-related itching was associated with a mean PAID score >20 (P = 0.01), and patients with more than one skin problem had an increased PAID score compared with those with one or no skin problems (P = 0.006).

CONCLUSIONS: More than half patients treated with CSII, CGM, or both had experienced skin problems during 4 months of follow-up that were associated with increased diabetes burden. Skin problems represent a persistent health issue affecting diabetes-specific emotional distress.

Original languageEnglish
JournalDiabetes Technology & Therapeutics
Volume21
Issue number4
Pages (from-to)215-221
Number of pages7
ISSN1520-9156
DOIs
Publication statusPublished - 1 Apr 2019

    Research areas

  • Continuous glucose monitoring, Continuous subcutaneous insulin infusion, Problem areas in diabetes, Skin problems, Type 1 diabetes.

ID: 56947139